Home › NDC Lookup › RxCUI directory › RxCUI 2362180

Opicapone 50 MG Oral Capsule — RxCUI 2362180

RxNorm drug concept · Semantic clinical drug
RxCUI 2362180 Semantic clinical drug · SCD ● Current RxNorm concept 2 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2362180
Official nameOpicapone 50 MG Oral Capsule
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
FDA products mapped2
Package NDCs mapped4
Reported Medicaid activity (SDUD)337 prescriptions · 2 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Opicapone: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Great question. Levodopa is still the main treatment, but for many people with Parkinson's it starts to wear off between doses — that's what's called an 'off' episode. Ongentys blo...
  • What exactly does Ongentys do — why is my doctor adding it to my levodopa?
  • Ongentys is taken once at bedtime, and food really does interfere with how well your body absorbs it — a meal can reduce absorption quite significantly. To get the full benefit, yo...
  • Why do I have to take it at bedtime and avoid eating around that time?
📖 Read our full Opicapone guide →

🕸️ Concept Web — How Opicapone 50 MG Oral Capsule Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Opicapone 50 MG Oral Capsule RxCUI 2362180

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Opicapone 2362167
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Ongentys 2362173
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Opicapone Oral Capsule 2362171
    • Opicapone Oral Product 2362169
    • Opicapone Pill 2362170
    • Opicapone Oral Capsule [Ongentys] 2362175
    • Ongentys Oral Product 2362176
    • Ongentys Pill 2362177
    • Oral Capsule 316965
    • Oral Product 1151131
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Opicapone 50 MG SCDC · 2362179
  • Opicapone Oral Capsule SCDF · 2362171
  • Opicapone Oral Product SCDG · 2362169
  • Opicapone Pill SCDG · 2362170

Brand-Name Concepts

  • Opicapone 50 MG Oral Capsule [Ongentys] SBD · 2362182
  • Opicapone 50 MG [Ongentys] SBDC · 2362181
  • Opicapone Oral Capsule [Ongentys] SBDF · 2362175
  • Ongentys Oral Product SBDG · 2362176
  • Ongentys Pill SBDG · 2362177
  • Ongentys BN · 2362173

📦 FDA Products & Package NDCs

2 products · 4 package NDCs
4 package NDCs map to RxCUI 2362180 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
64896-0402-01 30 CAPSULE in 1 BOTTLE (64896-402-01) ONGENTYS Amneal Pharmaceuticals LLC 2024-04-05
64896-0403-01 30 CAPSULE in 1 BOTTLE (64896-403-01) ONGENTYS Amneal Pharmaceuticals LLC 2024-04-05
64896-0403-02 7 CAPSULE in 1 BOTTLE (64896-403-02) ONGENTYS Amneal Pharmaceuticals LLC 2024-04-05
64896-0403-03 30 CAPSULE in 1 BOTTLE (64896-403-03) ONGENTYS Amneal Pharmaceuticals LLC 2024-04-05
Observed labelers: Amneal Pharmaceuticals LLC (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.